Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Jonesboro, AR
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Jonesboro, AR
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Los Angeles, CA
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Stanford, CA
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Stanford, CA
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Jacksonville, FL
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Orlando, FL
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
West Palm Beach, FL
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Augusta, GA
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Augusta, GA
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Baltimore, MD
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Boston, MA
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Kansas City, MO
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Hackensack, NJ
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Voorhees, NJ
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Voorhees, NJ
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Bornx, NY
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Bornx, NY
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Philadelphia, PA
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Seattle, WA
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Milwaukee, WI
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
FLT-PET Imaging for MDS
A Pilot Study for Using 18F-FLT PET Imaging To Assess Response In Patients With Myelodysplastic Syndrome (MDS) Being Treated With 5-azacitidine
Status: Enrolling
Updated:  12/23/2014
University of Wisconsin
mi
from
Madison, WI
FLT-PET Imaging for MDS
A Pilot Study for Using 18F-FLT PET Imaging To Assess Response In Patients With Myelodysplastic Syndrome (MDS) Being Treated With 5-azacitidine
Status: Enrolling
Updated: 12/23/2014
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated:  12/30/2014
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated: 12/30/2014
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated:  12/30/2014
Illinois Cancer Specialists
mi
from
Niles, IL
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated: 12/30/2014
Illinois Cancer Specialists
mi
from
Niles, IL
Click here to add this to my saved trials
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated:  12/30/2014
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated: 12/30/2014
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated:  12/30/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated: 12/30/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated:  12/30/2014
Massachusetts General Hospital
mi
from
Boston, MA
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated: 12/30/2014
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated:  12/30/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated: 12/30/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Thromboelastography During Surgery for Malignant Pleural Mesothelioma
Thromboelastography During Surgery for Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  1/28/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Thromboelastography During Surgery for Malignant Pleural Mesothelioma
Thromboelastography During Surgery for Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 1/28/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Peri-operative Assessment of Coagulopathy in Neonates and Infants Undergoing Cardiac Surgery
Peri-operative Assessment of Coagulopathy in Neonates and Infants Undergoing Cardiac Surgery
Status: Enrolling
Updated:  1/28/2015
Boston Children's Hospital
mi
from
Boston, MA
Peri-operative Assessment of Coagulopathy in Neonates and Infants Undergoing Cardiac Surgery
Peri-operative Assessment of Coagulopathy in Neonates and Infants Undergoing Cardiac Surgery
Status: Enrolling
Updated: 1/28/2015
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/12/2015
Georgia Regents University Augusta - Div. of Hematology/Oncology - BMT
mi
from
Agusta, GA
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/12/2015
Georgia Regents University Augusta - Div. of Hematology/Oncology - BMT
mi
from
Agusta, GA
Click here to add this to my saved trials
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/12/2015
Medical University of South Carolina
mi
from
Charleston, SC
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/12/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/12/2015
University of Utah Huntsman Cancer Institute - Div. of Hematology & Hematologic Malignncies
mi
from
Salt Lake City, UT
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/12/2015
University of Utah Huntsman Cancer Institute - Div. of Hematology & Hematologic Malignncies
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/12/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/12/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding
Estradiol Versus Tranexamic Acid on the Amount and Duration of Acute Cyclic Heavy Menstrual Bleeding
Status: Enrolling
Updated:  2/13/2015
Jones Institue Clinical Research Center
mi
from
Norfolk, VA
Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding
Estradiol Versus Tranexamic Acid on the Amount and Duration of Acute Cyclic Heavy Menstrual Bleeding
Status: Enrolling
Updated: 2/13/2015
Jones Institue Clinical Research Center
mi
from
Norfolk, VA
Click here to add this to my saved trials
Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding
Estradiol Versus Tranexamic Acid on the Amount and Duration of Acute Cyclic Heavy Menstrual Bleeding
Status: Enrolling
Updated:  2/13/2015
Sentara Norfolk General Emergency Department
mi
from
Norfolk, VA
Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding
Estradiol Versus Tranexamic Acid on the Amount and Duration of Acute Cyclic Heavy Menstrual Bleeding
Status: Enrolling
Updated: 2/13/2015
Sentara Norfolk General Emergency Department
mi
from
Norfolk, VA
Click here to add this to my saved trials
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
A Pilot Study to Determine the Safety and Efficacy of Using Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
Status: Enrolling
Updated:  2/13/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
A Pilot Study to Determine the Safety and Efficacy of Using Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
Status: Enrolling
Updated: 2/13/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia
A Phase 1, Open-Label, Single-Dose, Sequential Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia
Status: Enrolling
Updated:  3/3/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia
A Phase 1, Open-Label, Single-Dose, Sequential Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia
Status: Enrolling
Updated: 3/3/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia
A Phase 1, Open-Label, Single-Dose, Sequential Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia
Status: Enrolling
Updated:  3/3/2015
Clinical Research Facility
mi
from
Seattle, WA
Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia
A Phase 1, Open-Label, Single-Dose, Sequential Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia
Status: Enrolling
Updated: 3/3/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
HSCT for High Risk Inherited Inborn Errors
Treatment of High Risk, Inherited Lysosomal And Peroxisomal Disorders by Reduced Intensity Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  4/22/2015
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
HSCT for High Risk Inherited Inborn Errors
Treatment of High Risk, Inherited Lysosomal And Peroxisomal Disorders by Reduced Intensity Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 4/22/2015
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients-Pilot Study
Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients - Pilot Study
Status: Enrolling
Updated:  4/24/2015
CAMC Health Systems
mi
from
Charleston, WV
Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients-Pilot Study
Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients - Pilot Study
Status: Enrolling
Updated: 4/24/2015
CAMC Health Systems
mi
from
Charleston, WV
Click here to add this to my saved trials
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, a Hypoxia-Activated Prodrug, in Patients With Advanced Leukemias
Status: Enrolling
Updated:  5/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, a Hypoxia-Activated Prodrug, in Patients With Advanced Leukemias
Status: Enrolling
Updated: 5/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
CNDO-109-AANK for AML in First Complete Remission (CR1)
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Status: Enrolling
Updated:  5/5/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
CNDO-109-AANK for AML in First Complete Remission (CR1)
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Status: Enrolling
Updated: 5/5/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
CNDO-109-AANK for AML in First Complete Remission (CR1)
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Status: Enrolling
Updated:  5/5/2015
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
CNDO-109-AANK for AML in First Complete Remission (CR1)
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Status: Enrolling
Updated: 5/5/2015
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
CNDO-109-AANK for AML in First Complete Remission (CR1)
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Status: Enrolling
Updated:  5/5/2015
Washington University
mi
from
St. Louis, MO
CNDO-109-AANK for AML in First Complete Remission (CR1)
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Status: Enrolling
Updated: 5/5/2015
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
CNDO-109-AANK for AML in First Complete Remission (CR1)
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Status: Enrolling
Updated:  5/5/2015
Medical University of South Carolina
mi
from
Charleston, SC
CNDO-109-AANK for AML in First Complete Remission (CR1)
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Status: Enrolling
Updated: 5/5/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Promacta Pregnancy Registry
Promacta Pregnancy Registry
Status: Enrolling
Updated:  5/8/2015
GSK Investigational Site
mi
from
Research Triangle Park, NC
Promacta Pregnancy Registry
Promacta Pregnancy Registry
Status: Enrolling
Updated: 5/8/2015
GSK Investigational Site
mi
from
Research Triangle Park, NC
Click here to add this to my saved trials
Evaluation of Hemostasis in Bleeding and Thrombotic Disorders
Evaluation of Hemostasis in Bleeding and Thrombotic Disorders Using the Roteg Analyzer and the Thrombin Generation Assay
Status: Enrolling
Updated:  6/11/2015
The Univerisity of Texas Health Science Center at Houston
mi
from
Houston, TX
Evaluation of Hemostasis in Bleeding and Thrombotic Disorders
Evaluation of Hemostasis in Bleeding and Thrombotic Disorders Using the Roteg Analyzer and the Thrombin Generation Assay
Status: Enrolling
Updated: 6/11/2015
The Univerisity of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency
Status: Enrolling
Updated:  6/19/2015
Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield
mi
from
Springfield, MO
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency
Status: Enrolling
Updated: 6/19/2015
Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield
mi
from
Springfield, MO
Click here to add this to my saved trials
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency
Status: Enrolling
Updated:  6/19/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency
Status: Enrolling
Updated: 6/19/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Study of Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma (CTCL)
Status: Enrolling
Updated:  6/19/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Study of Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma (CTCL)
Status: Enrolling
Updated: 6/19/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
Busulfan (IV) and Fludarabine Followed by Post-allogeneic Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies.
Status: Enrolling
Updated:  7/2/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
Busulfan (IV) and Fludarabine Followed by Post-allogeneic Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies.
Status: Enrolling
Updated: 7/2/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults With Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  7/2/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults With Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 7/2/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults With Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  7/2/2015
Mayo Clinic Florida
mi
from
Jacksonville, FL
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults With Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 7/2/2015
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults With Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  7/2/2015
Tufts Medical Center
mi
from
Boston, MA
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults With Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 7/2/2015
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials